Point Mutations in Retargeted gD Eliminate the Sensitivity of EGFR/EGFRvIII-Targeted HSV to Key Neutralizing Antibodies

Effective oncolytic virotherapy may require systemic delivery, tumor targeting, and resistance to virus-neutralizing (VN) antibodies. Since herpes simplex virus (HSV) glycoprotein D (gD) is the viral attachment/entry protein and predominant VN target, we examined the impact of gD retargeting alone a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuzmen, Ceren, Cairns, Tina M., Atanasiu, Doina, Lou, Huan, Saw, Wan Ting, Hall, Bonnie L., Cohen, Justus B., Cohen, Gary H., Glorioso, Joseph C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000558/
https://www.ncbi.nlm.nih.gov/pubmed/32042851
http://dx.doi.org/10.1016/j.omtm.2019.12.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000558/
https://www.ncbi.nlm.nih.gov/pubmed/32042851
http://dx.doi.org/10.1016/j.omtm.2019.12.013

Ejemplares similares